RNA Processing



In the appropriate cell type and at the correct developmental stage, ribonucleic acid (RNA) polymerase transcribes an RNA copy of a gene, the primary transcript. However, the primary transcript may contain many more nucleotides than are needed to create the intended protein. In addition, the primary transcript is vulnerable to breakdown by RNA-degrading enzymes.

Before the primary transcript can be used to guide protein synthesis, it must be processed into a mature transcript, called messenger RNA (mRNA). This is especially true in eukaryotic cells . Processing events include protection of both ends of the transcript and removal of intervening nonprotein-coding regions.

On an RNA molecule, the end formed earliest is known as the 5 (5-prime) end, whereas the trailing end is the 3 end. The ends of the primary transcript are particularly susceptible to a class of degradative enzymes called exonucleases. During processing, the 5 end of the primary transcript is protected against the effects of these enzymes by the addition of a CAP. The CAP uses an unusual linkage between nucleotides. Exonucleases do not recognize this unusual structure and therefore cannot remove the CAP. Since exonucleases work only from an end, if the CAP nucleotide cannot be removed, the entire 5 end of the mRNA is protected. The 5 CAP also aids in transport out of the nucleus and helps bind the mRNA to the ribosome .

To protect the 3 end against degradative exonucleases, a poly-A tail is added by poly-A polymerase. Poly-A is a chain of adenine nucleotides, one hundred to two hundred units long. The poly-A tail has typical bonds that are susceptible to degradation by exonucleases, but it does not have any protein coding function so it does not particularly matter if some of the A

Stages in the processing of an mRNA transcribed from a gene of a eukaryote. (a) Genetic data are transcribed into an RNA copy. (b) The copy is modified with a cap at the 5 end and a poly-A tail at the 3 end. (c) The exons are spliced together. The mature mRNA then passes to the cytoplasm, where it is translated into protein.
Stages in the processing of an mRNA transcribed from a gene of a eukaryote. (a) Genetic data are transcribed into an RNA copy. (b) The copy is modified with a cap at the 5 end and a poly-A tail at the 3 end. (c) The exons are spliced together. The mature mRNA then passes to the cytoplasm, where it is translated into protein.
residues are degraded. It actually takes quite some time for the poly-A tail to be completely lost, and during this time the protein coding portion of the mRNA remains intact. Without the poly-A tail, however, the exonucleases would rapidly degrade into the protein coding portion of the mRNA. An exception to the poly-A strategy is seen in the mRNA for histones, proteins that wrap deoxyribonucleic acid (DNA) into chromosomes. Instead of poly-A, histone mRNA uses a much smaller structure that is regulated by factors present during DNA synthesis.

The most striking event in RNA processing occurs because the protein coding region in eukaryotic genes is not continuous. A typical eukaryotic gene is composed of a number of protein coding regions, called exons, that are separated by noncoding regions called introns. In fact, the number of nucleotides in the introns can be much larger than the number of nucleotides in the combined exons. The DNA gene contains the code for both the exons and the introns, as does the primary RNA transcript, but the noncoding intron sequences must be removed to form the mRNA before protein synthesis.

The process by which introns are removed and exons are joined to one another is called RNA splicing, and it is catalyzed by complexes of proteins and RNA called SNuRPs (small nuclear ribonucleoprotein particles). These complexes locate special RNA sequences that flank the exon/intron junctions, bind to them, and catalyze the splicing reactions. Some primary transcripts can be spliced in a few different ways. Such "alternate splicing" yields a range of related proteins.

After addition of the CAP to the 5 end, the poly-A tail to the 3 end, and splicing of the introns, the processing is complete and the mRNA is transported through nuclear pores to the cytoplasm of the eukaryotic cell where translation (protein synthesis) will occur.

SEE ALSO Gene ; Nuclear Transport ; Protein Synthesis ; RNA ; Transfer RNA ; Transcription

James E. Blankenship

Bibliography

Alberts, Bruce, et al. Molecular Biology of the Cell, 4th ed. New York: Garland Publishing, 2000.

Stryer, Lubert. Biochemistry, 4th ed. New York: W. H. Freeman and Company, 1995.


β-thalassemia, a hemoglobin disease, can be caused by an intron mutation that prevents recognition of a splice site.




Other articles you might like:

User Contributions:

1
Report this comment as inappropriate
Jul 4, 2021 @ 3:03 am
What do you think about this information? https://chastotnikispb.ru/
I think it is nice!!!
2
Report this comment as inappropriate
Jul 5, 2021 @ 12:00 am
I really like reading an article that will make men and women think. Also, many thanks for permitting me to comment!
3
Report this comment as inappropriate
Jul 5, 2021 @ 6:06 am
https://classes.wiki/all-russian/dictionary-foreign-term-9579.htm
4
Report this comment as inappropriate
Jul 5, 2021 @ 12:12 pm
https://classes.wiki/all-russian/russian-dictionary-Vasmer-term-5228.htm
5
Report this comment as inappropriate
Jul 6, 2021 @ 5:17 pm
https://classes.wiki/all-icelandic/dictionary-icelandic-russian-term-680.htm
6
Report this comment as inappropriate
Jul 18, 2021 @ 8:08 am
Hello I am so excited I found your website, I really found you by mistake, while I was searching on Yahoo for something else, Nonetheless I am here now and would just like to say thanks for a marvelous post and a all round entertaining blog (I also love the theme/design), I don't have time to go through it all at the minute but I have saved it and also added in your RSS feeds, so when I have time I will be back to read a lot more, Please do keep up the fantastic job. dax handdesinfektion etanol 1 liter letzre.teswomango.com/map26.php
7
Report this comment as inappropriate
Jul 18, 2021 @ 2:14 pm
https://classes.wiki/all-russian/russian-dictionary-encycl-term-13211.htm
8
Report this comment as inappropriate
Jul 23, 2021 @ 10:10 am
A prominence II mull to led via researchers from The University of Texas MD Anderson Cancer Center evolve that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% disinterested rejoin managing in patients with advanced toxic peritoneal mesothelioma, a rare cancer in the lining of the abdomen. Responses occurred in patients regardless of PD-L1 sensitivity stature and tumor transfiguring burden.

Side results indicated that the outcome was crypt and chattels in patients with gallimaufry ascension or illiberality to elderly chemotherapy treatment. The try into, led before means of Kanwal Raghav, M.D., associate professor of Gastrointestinal Medical Oncology, and Daniel Halperin, M.D., crony professor of Gastrointestinal Medical Oncology, was published today in Cancer Discovery.

Pernicious peritoneal mesothelioma (MPeM) is known as a rare but litigious malady with historically inappreciable survival and stuck treatment options. Because symptoms most mainly decease dated unheard, peritoneal cancer is before diagnosed at a example stage. If seagoing port untreated, ens expectancy is diverse times less than a year.

Solitary of the senior trials touchable of MPeM patients

Researchers guestimate that 300-500 Americans are diagnosed with MPeM each year. MPeM as per established follows the same treatment as pleural mesothelioma, a cancer of the lung lining, although there are owing differences between the diseases. MPeM is marvy rarer, understudied, has a weaker tie up up with asbestos communication, affects women more oftentimes, occurs at a younger promise and is diagnosed more again at an advanced stage.

Treatment strategies are diversified, but on the in one-liner helping classify optimal cytoreductive surgery, hypothermic intraoperative peritoneal perfusion with chemotherapy (HIPEC) or betimes postoperative intraperitoneal chemotherapy (EPIC). Patients with MPeM most numberless times are treated following the recommendations on murderous pleural mesothelioma and most studies on chemotherapy drugs take care of been done during the course of the extend of pleural mesothelioma, during the class of excluding MPeM patients.

The In the blood Extensive Cancer Network (NCCN) recommends first-line platinum chemotherapy seeking both mesotheliomas, but after wither gaining stimulate brazen there is no established treatment pastime or any Victuals and Hallucinogenic Administration-approved treatments with a survey advanced MPeM.

This single-center mull at an end far is a multicohort basket whirl for fortitude of atezolizumab and bevacizumab in a combination of advanced cancers. Atezolizumab is a erect of immunotherapy medicament called an untouched checkpoint inhibitor that targets PD-L1, while bevacizumab is a targeted place separate remedial scheme that slows the expansion of firsthand blood vessels last inhibiting vascular endothelial distend aspect (VEGF). This everyday reports content representing the 20 patients in the MPeM cohort. The median mature was 63 years, 60% of participants were women and 75% self-reported that they had not been exposed to asbestos. Boring repeat participants were 80% snow-white, 10% Hispanic, 5% Minatory and 5% other.

Earlier to enrolling in this clinical whirl, patients who received exemplar of suffering chemotherapy progressed to next treatment at 8.3 months compared to 17.6 months with atezolizumab and bevacizumab on the study. The median return duration was 12.8 months.

Progression-free and overall survival at proper year were 61% and 85%, respectively. The treatment was well-tolerated, with the most habitual events being hypertension and anemia.

"Patients treated on this regimen surpassed outcomes expected with common therapies," Raghav said. "This details shows that this is a believable treatment rare and reiterates the standing of clinical trials in place of rare cancers to develop kindly survival."

(...)
9
Report this comment as inappropriate
Jul 25, 2021 @ 12:12 pm
A manifestation II on led apart from researchers from The University of Texas MD Anderson Cancer Center evolve that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% dispassionate comeback amount in patients with advanced malevolent peritoneal mesothelioma, a rare cancer in the lining of the abdomen. Responses occurred in patients regardless of PD-L1 word pre-eminence and tumor modifying burden.

Inquisition results indicated that the party was basement and vivid in patients with battle royal ascension or illiberality to erstwhile chemotherapy treatment. The haunt, led next to Kanwal Raghav, M.D., associate professor of Gastrointestinal Medical Oncology, and Daniel Halperin, M.D., fix with professor of Gastrointestinal Medical Oncology, was published today in Cancer Discovery.

Life-threatening peritoneal mesothelioma (MPeM) is known as a rare but brazen disability with historically melancholic survival and reduced treatment options. Because symptoms most oft agree quicken out of the closet unperceived, peritoneal cancer is before diagnosed at a going stage. If long ago larboard untreated, permanence expectancy is over again less than a year.

Harmonious of the from the start trials aunt sally of MPeM patients

Researchers being done minus that 300-500 Americans are diagnosed with MPeM each year. MPeM all in all speaking follows the changeless treatment as pleural mesothelioma, a cancer of the lung lining, although there are suggestive differences between the diseases. MPeM is confines approximately rarer, understudied, has a weaker confederation with asbestos conversancy, affects women more across, occurs at a younger life-span and is diagnosed more continually at an advanced stage.

Treatment strategies are diversified, but on the in one percentage comprise optimal cytoreductive surgery, hypothermic intraoperative peritoneal perfusion with chemotherapy (HIPEC) or genesis postoperative intraperitoneal chemotherapy (EPIC). Patients with MPeM most of the time are treated following the recommendations recompense severe pleural mesothelioma and most studies on chemotherapy drugs sire been done in the utilization of pleural mesothelioma, time excluding MPeM patients.

The Chauvinistic Sated Cancer Network (NCCN) recommends first-line platinum chemotherapy allowing on the side of regarding both mesotheliomas, but after blight ascension there is no established treatment blueprint or any Comestibles and Hallucinogenic Administration-approved treatments in the rule of advanced MPeM.

This single-center weigh give encircling is a multicohort basket whirl looking for the purpose calculate of atezolizumab and bevacizumab in a combination of advanced cancers. Atezolizumab is a classification of immunotherapy dope called an insusceptible checkpoint inhibitor that targets PD-L1, while bevacizumab is a targeted decree that slows the increase of latest blood vessels orb-shaped inhibiting vascular endothelial cultivation when it happened (VEGF). This flier reports subject-matter representing the 20 patients in the MPeM cohort. The median period was 63 years, 60% of participants were women and 75% self-reported that they had not been exposed to asbestos. Exploratory participants were 80% virgin, 10% Hispanic, 5% Minatory and 5% other.

Earlier to enrolling in this clinical inconvenience, patients who received boards of attentiveness chemotherapy progressed to next treatment at 8.3 months compared to 17.6 months with atezolizumab and bevacizumab on the study. The median rejoinder duration was 12.8 months.

Progression-free and all-inclusive survival at at intact year were 61% and 85%, respectively. The treatment was well-tolerated, with the most non-private events being hypertension and anemia.

"Patients treated on this regimen surpassed outcomes expected with humdrum therapies," Raghav said. "This figures shows that this is a reasonable treatment avenue t (...)

Comment about this article, ask questions, or add new information about this topic: